# Oncodesign Precision Medicine

Source: https://onco.cc/companies/oncodesign-precision-medicine/  
OnCo record `oncodesign-precision-medicine` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oncodesign Precision Medicine is a small French company developing kinase-blocking medicines. Its OPM-101 is being prepared for a trial with pembrolizumab in advanced melanoma that no longer responds to immunotherapy.

## Summary

Oncodesign Precision Medicine (OPM; ISIN FR001400CM63, ticker ALOPM), based in Dijon, was founded in 2022, according to the company, and specialises in precision medicine for resistant and metastatic cancers; it was co-founded by Philippe Genne, Jan Hoflack and Karine Lignel and employs 14 people. Its two clinical kinase inhibitors come from the Nanocyclix platform of macrocyclic kinase inhibitors: OPM-101, studied in healthy volunteers and now intended for immuno-oncology and chronic inflammatory bowel disease, and OPM-201, a Parkinson's disease programme funded by the Michael J. Fox Foundation. The REVERT phase 1b/2a protocol of OPM-101 with pembrolizumab in advanced melanoma resistant to anti-PD-1 was approved by Swiss regulatory and ethics authorities in late 2025 and was still in preparation in October 2026 (NCT07040436). The company reported a cash position of EUR 2.86 million at 30 June 2026. Its first registered interventional cancer trial, NCT07040436, was posted on ClinicalTrials.gov in June 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: OPM
- HQ: Dijon
- Type: biotech
- Website: https://www.oncodesign.com/
- Ticker: ALOPM

## Notes

- Founding year, ticker, HQ and trial status from the October 2026 half-year results release, read on 29 October 2026.
- The molecular target of OPM-101 is not stated in the material read, so no target is linked.
- An earlier observational study (OncoSNIPE, NCT04548960, posted 2020) was sponsored by the former parent Oncodesign SA, not by OPM.
- The release states the accounts were prepared on a going concern basis with details to follow in the half-year report; that report was not read.

## Sources

- Official website: https://www.oncodesign.com/
- 2026 half-year results release (PDF): https://www.oncodesign.com/wp-content/uploads/2026/10/PR_OPM_HYR-26_EN_22102026.pdf
- ClinicalTrials.gov: REVERT phase 1b/2a trial of OPM-101 (NCT07040436): https://clinicaltrials.gov/study/NCT07040436

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)

---
JSON: https://onco.cc/api/v1/entities/oncodesign-precision-medicine.json